A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer | Zendy

M. Michael | Zendy; John Zalcberg | Zendy; Peter Gibbs | Zendy; Lara Lipton | Zendy; Maëlenn Gouillou | Zendy; Michael Jefford | Zendy; Grant A. McArthur | Zendy; Michael Copeman | Zendy; Kevin Lynch | Zendy; N. C. Tebbutt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer

Author(s) -

M. Michael,

John Zalcberg,

Peter Gibbs,

Lara Lipton,

Maëlenn Gouillou,

Michael Jefford,

Grant A. McArthur,

Michael Copeman,

Kevin Lynch,

N. C. Tebbutt

Publication year - 2012

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-012-2009-5

Subject(s) - medicine , imatinib , neutropenia , bevacizumab , oxaliplatin , colorectal cancer , oncology , febrile neutropenia , pharmacokinetics , chemotherapy , phases of clinical research , gastroenterology , pharmacology , imatinib mesylate , irinotecan , cancer , myeloid leukemia

Platelet-derived growth factor receptor (PDGFR) inhibition by reducing tumoral interstitial fluid pressure might increase the efficacy of chemotherapy. Imatinib inhibits PDGFR kinase activity at therapeutically relevant doses. This phase I study aimed to assess the maximal tolerated dose (MTD) of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer and to identify pharmacokinetic (PK) interactions and toxicities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research